Kirkland & Ellis is advising CD&R on the M&A and reinvestment aspects as it enters into exclusive negotiations with Sanofi to acquire a 50% controlling stake in consumer healthcare champion, Opella, with Sanofi remaining a significant shareholder. CD&R’s acquisition of a controlling stake values Opella at approximately €16 billion (EV). Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 strategic manufacturing sites and four science and innovation development centers. Opella is the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market, serving more than half a billion consumers worldwide.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
